TALWIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TALWIN (TALWIN).
Agonist at kappa-opioid receptors and antagonist at mu-opioid receptors; produces analgesia through spinal and supraspinal mechanisms.
| Metabolism | Hepatic metabolism via oxidation and glucuronidation; CYP450 enzymes minimally involved; major metabolites include norpentazocine. |
| Excretion | Renal: 60-70% as unchanged drug and metabolites (pentazocine and its glucuronide conjugate); biliary/fecal: 20-30% |
| Half-life | 2-3 hours in adults; prolonged to 4-6 hours in hepatic impairment; clinical context: short half-life necessitates frequent dosing for chronic pain |
| Protein binding | 60-70% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein) |
| Volume of Distribution | 3-5 L/kg; clinical meaning: extensive tissue distribution, including CNS |
| Bioavailability | Oral: 20-40% due to extensive first-pass metabolism; Intramuscular: 90-100% |
| Onset of Action | Intravenous: 2-3 minutes; Intramuscular: 15-20 minutes; Oral: 15-30 minutes |
| Duration of Action | Intravenous: 1-2 hours; Intramuscular: 2-3 hours; Oral: 3-4 hours; clinical note: duration is dose-dependent and may be shorter with higher doses due to ceiling effect |
50 mg orally every 3-4 hours as needed; maximum 600 mg/day. For severe pain, 30 mg intramuscularly or subcutaneously every 3-4 hours; maximum 360 mg/day parenterally.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: Administer 75% of usual dose every 6-8 hours. GFR 10-29 mL/min: Administer 50% of usual dose every 8-12 hours. GFR <10 mL/min: Administer 25% of usual dose every 12 hours. |
| Liver impairment | Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6-8 hours. Child-Pugh Class C: Administer 25% of usual dose every 8-12 hours. |
| Pediatric use | Not recommended for pediatric use due to lack of safety and efficacy data in children under 12 years. For children 12 years and older, dosing per adult guidelines. |
| Geriatric use | Initiate at 50 mg orally every 6 hours; use lower parenteral doses (e.g., 30 mg IM/SC every 4-6 hours). Titrate cautiously due to increased sensitivity and risk of respiratory depression. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TALWIN (TALWIN).
| Breastfeeding | Pentazocine is excreted into breast milk in small amounts; estimated infant dose is <1% of maternal weight-adjusted dose. M/P ratio not reported. Use caution; monitor infant for respiratory depression and sedation. |
| Teratogenic Risk | Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of skeletal anomalies at high doses. Second and third trimesters: Prolonged use may cause fetal opioid dependence and neonatal withdrawal syndrome. Avoid use during labor due to risk of neonatal respiratory depression. |
■ FDA Black Box Warning
Risk of respiratory depression, particularly in elderly or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
| Serious Effects |
Hypersensitivity to pentazocine; severe respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen.
| Precautions | Respiratory depression especially with CNS depressants; increased intracranial pressure; seizure risk; biliary tract spasm; renal/hepatic impairment; drug dependence potential; withdrawal reactions. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal respiratory rate, blood pressure, and level of sedation during therapy. For prolonged use, assess fetal growth and monitor for signs of neonatal opioid withdrawal. During labor, have resuscitation equipment available. |
| Fertility Effects | May impair female fertility by interfering with ovulation or implantation based on animal studies. Clinical significance in humans is unknown. |